|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||25.20 - 28.47|
|52 Week Range||3.00 - 32.69|
|Beta (5Y Monthly)||1.78|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 11, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the underwriters have exercised their option (the "Option") to purchase an additional 724,637 common shares in the capital of the Company (the "Common Shares"), in connection with the Company's recently completed underwritten public offering of 4,830,918 Common Shares, which closed on February 22, 2021 (the "Offering"). On closing of the Option, the Company will have issued 5,555,555 Common Shares pursuant to the Offering for gross proceeds of approximately $150 million.
ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX) (TSX-V: EPI), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on February 25, 2021 (the "Meeting").
HOUSTON, Texas and VANCOUVER, Canada, Feb. 25, 2021 /CNW/ - ESSA Pharma Inc.